GIP/GLP-1 Dual Agonists Billing & Prior-Auth Playbook

What Are GIP/GLP-1 Dual Agonists?

GIP/GLP-1 dual agonists simultaneously activate glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism produces larger glucose-lowering and weight-loss effects than selective GLP-1 receptor agonists alone. Tirzepatide is the class prototype and, as of 2025, the only approved agent, though several investigational dual and triple agonists are in phase 2 and 3 development.

Mechanism and Clinical Differentiation

GIP receptor activation augments insulin secretion, suppresses glucagon, and may directly reduce adipose tissue inflammation. GLP-1 receptor activation slows gastric emptying, reduces appetite, and increases satiety signaling in the hypothalamus. Together, these pathways explain why tirzepatide consistently outperformed semaglutide 1 mg in the SURPASS-2 trial (N=1,879): tirzepatide 15 mg produced a 2.58% mean A1c reduction vs. 2.33% for semaglutide, and 12.4 kg mean weight loss vs. 6.2 kg at 40 weeks 1.

Approved Indications Through Mid-2025

Tirzepatide carries three distinct FDA approvals. Mounjaro received approval in May 2022 for glycemic control in adults with type 2 diabetes mellitus 2. Zepbound received approval in November 2023 for chronic weight management in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity 3. The FDA then expanded Zepbound's label in 2024 to include moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, based on SURMOUNT-OSA data showing a 27.4-event-per-hour median reduction in apnea-hypopnea index in the CPAP-naive group (N=234) 4.

The FDA also accepted a supplemental application for heart failure with preserved ejection fraction (HFpEF) following SUMMIT trial results showing tirzepatide reduced the primary composite endpoint of cardiovascular death or worsening heart failure by 38% (HR 0.62; 95% CI 0.41-0.95) vs. Placebo 5.

ICD-10 Documentation: Getting the Diagnosis Code Right

The single most common reason a prior authorization is denied before a human reviewer ever sees it is an incorrect or insufficiently specific ICD-10 code. Payers map your diagnosis code to the contracted coverage policy automatically.

Obesity Codes and BMI Modifiers

For Zepbound (obesity indication), the primary code must specify severity:

• E66.01, Morbid (severe) obesity due to excess calories (BMI ≥40, or ≥35 with comorbidity). This is the strongest code for PA approval.
• E66.09, Other obesity due to excess calories (BMI 30.0-39.9 without severe comorbidity). Use when BMI criteria meet Zepbound's label but not the morbid threshold.
• E66.9, Obesity, unspecified. Avoid this code entirely. Most payers reject it automatically because it lacks specificity.

Pair the obesity code with a Z68.xx BMI code to provide numeric evidence. For example, a patient with BMI 37.4 would carry Z68.37. The American Medical Association CPT guidelines do not require a separate charge for BMI calculation; document it in the visit note and list the Z68 code as a secondary diagnosis 6.

Type 2 Diabetes Codes for Mounjaro

For Mounjaro (T2D indication):

• E11.65, Type 2 diabetes with hyperglycemia. Use when A1c remains above goal.
• E11.649, Type 2 diabetes with hypoglycemia without coma. Add when you are switching from sulfonylurea to reduce hypoglycemia risk.
• E11.9, Type 2 diabetes without complications. Acceptable, but pairing with a complication code (e.g., E11.21 for diabetic CKD stage 3) strengthens the medical necessity argument.

Include current A1c in the clinical notes. Payers often request the most recent lab value dated within 90 days. A documented A1c ≥7.5% despite at least one prior oral agent almost always satisfies the "inadequate control" criterion that most commercial formularies require 7.

Comorbidity Codes That Strengthen Any PA

Adding comorbidity codes is not optional decoration. Each additional code maps to a higher medical necessity tier in most payer algorithms:

• G47.33, Obstructive sleep apnea (adult). Required for the OSA indication; also strengthens obesity PA submissions.
• I50.32, Chronic diastolic (congestive) heart failure. Maps to the HFpEF evidence base.
• N18.3-N18.4, Chronic kidney disease stage 3a-3b. Adds nephroprotection rationale; tirzepatide's renal safety profile was characterized in SURPASS-4 8.
• E78.5, Hyperlipidemia, unspecified. Documented metabolic comorbidity.

Prior Authorization Requirements by Payer Type

Commercial Insurance

Commercial plan PA criteria for tirzepatide vary by plan but share a recognizable core structure. Most require:

1. BMI documentation from a visit within 6 months (obesity indication) or an A1c from within 90 days (T2D indication).
2. Step-therapy failure. For the obesity brand (Zepbound), many plans require a documented 3-to-6-month trial of a lifestyle intervention program, and some require a prior trial of orlistat or phentermine/topiramate. For Mounjaro, plans typically require documented inadequate glycemic control on metformin plus one of: a sulfonylurea, SGLT-2 inhibitor, or DPP-4 inhibitor.
3. Prescriber specialty attestation. Some plans require the prescribing provider to be an endocrinologist, primary care physician, or obesity medicine specialist. Confirm specialty mapping before submitting.
4. Quantity limits. Most commercial formularies approve tirzepatide at the starting dose (2.5 mg weekly) for the first 90 days, then require a dose-escalation visit or lab update before approving 5 mg and above.

The Endocrine Society's 2023 clinical practice guideline states: "Pharmacotherapy should be considered for individuals with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities who have not achieved clinically meaningful weight loss through lifestyle intervention alone" 9.

Medicare Part D

Medicare Part D plans gained the ability to cover obesity medications for the first time under the Treat and Reduce Obesity Act provisions included in the Inflation Reduction Act, though full implementation details continued to evolve through 2025. As of 2025, most standalone Part D plans and Medicare Advantage plans do not cover Zepbound (obesity-only indication) without a separate rider. Mounjaro is covered under Part D when the T2D diagnosis is primary. Prescribers billing Medicare should note:

• Submit with ICD-10 E11.xx as primary for Mounjaro.
• Document that lifestyle intervention was attempted per CMS chronic condition documentation requirements 10.
• Use NDC 00002-1530-xx for Mounjaro (verify current lot-specific NDC at point of dispensing).

Medicaid

State Medicaid coverage is highly variable. As of mid-2025, fewer than half of state Medicaid programs cover tirzepatide for obesity without a prior GLP-1 failure requirement. States that follow ADA Standards of Care 7 more closely in their preferred drug list (PDL) design tend to approve Mounjaro after a single prior agent failure. Check your state's PDL at Medicaid.gov or directly at the state pharmacy program office before submitting.

Employer Self-Insured Plans (ERISA)

ERISA plans set their own PA criteria outside state insurance mandates. Some large self-insured employers have added tirzepatide to their formulary as a covered benefit with a $0 or low-copay tier as part of a cardiovascular risk-reduction program. Others apply BMI caps (e.g., requiring BMI ≥35 regardless of comorbidities). When you hit a BMI cap denial, the appeal should cite SURMOUNT-1 data: at a BMI of 30.0-34.9 with at least one comorbidity, tirzepatide 15 mg still produced 19.5% mean weight loss at 72 weeks in the subgroup analysis 11.

Step Therapy: What Counts as a Covered Prior Trial

T2D Step Therapy

For Mounjaro, most commercial plans accept any of the following as prior therapy documentation:

• Metformin at ≥1,500 mg/day for ≥3 months with documented A1c above goal.
• Metformin plus a sulfonylurea (e.g., glipizide ≥5 mg/day) for ≥3 months with A1c above goal or documented hypoglycemia requiring dose reduction.
• Metformin plus an SGLT-2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) for ≥3 months with A1c above goal.

Clinically, if a patient has contraindications to metformin (eGFR <30 mL/min/1.73m², active liver disease, lactic acidosis history), document the contraindication explicitly. Payers are required to waive step therapy under most state laws when a clinical contraindication exists.

Obesity Step Therapy

For Zepbound, the step requirements are less standardized but commonly include:

• Documentation of a supervised behavioral or dietary intervention lasting ≥6 months with <5% weight loss. Programs like the CDC-recognized Diabetes Prevention Program (DPP) count as documented lifestyle therapy 12.
• Prior trial of an FDA-approved anti-obesity medication (AOM). Plans vary on whether they require a GLP-1 (semaglutide/liraglutide) or accept any AOM (phentermine, orlistat, bupropion/naltrexone, phentermine/topiramate).

When step therapy requires a prior GLP-1 trial, document that the patient was switched to tirzepatide due to insufficient efficacy, not intolerance, if possible. A <5% weight loss on semaglutide 2.4 mg (Wegovy) over 16 weeks is considered inadequate response and satisfies most step criteria. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% placebo 13, so a patient losing less than 5% on the full dose is clearly in the non-responder category.

Submitting the PA: Checklist and Common Errors

The following framework covers the minimum documentation set for a high-probability first-pass approval. Organize the PA packet in this order:

Required Documentation Packet

1. PA request form (payer-specific; confirm fax number vs. Portal submission preference).
2. Recent office note (within 6 months for obesity; within 90 days for T2D) including current weight, BMI, vital signs, and relevant comorbidities.
3. Lab results: A1c within 90 days (T2D); lipid panel within 12 months; renal function (BMP or CMP) within 12 months; liver enzymes if NAFLD/MASLD is a documented comorbidity.
4. Step therapy documentation: Chart notes or pharmacy records showing dates, doses, and outcomes of required prior agents.
5. Prescriber attestation letter: A signed statement from the prescribing provider citing specific trial data and guideline language supporting medical necessity.
6. NDC and brand specificity: Submit the NDC for the exact brand (Mounjaro vs. Zepbound). Payers process these under different benefit categories (pharmacy vs. Medical) in some plans.

Common Submission Errors That Cause Automatic Denial

• Submitting Zepbound under a T2D-only benefit when the patient does not carry an E11.xx code.
• Missing quantity limit justification when requesting a dose above 5 mg at initial submission.
• Using a non-specific obesity code (E66.9) instead of E66.01 or E66.09.
• Step therapy dates that fall within the same calendar year and appear too recent (less than 90 days of documented prior therapy).
• Submitting a fax to a number that routes to a different payer's PA department (verify the plan ID against the insurance card at every submission).

Denial Management and Appeals

First-Level Administrative Appeal

File within the payer's window (typically 30-60 days from denial). Include the denial letter, the original PA packet, and a cover letter citing:

• The specific denial reason (formulary exclusion, step therapy not met, not medically necessary).
• The clinical trial data refuting the denial rationale. For "not medically necessary" denials, SURMOUNT-1 (N=2,539, tirzepatide 15 mg, 22.5% mean weight loss at 72 weeks) 11 is the strongest anchor.
• Guideline alignment. The 2023 American Gastroenterological Association (AGA) Clinical Practice Guideline for obesity pharmacotherapy recommends tirzepatide as a preferred agent based on its efficacy and tolerability profile 14.

Peer-to-Peer Review

Request a peer-to-peer (P2P) call if the first administrative appeal fails. Most payers are required to arrange this within 3 business days of request. Bring the following to the call:

• Current weight, BMI, and comorbidity burden.
• Prior medication history with documented outcomes.
• Specific trial outcomes at the approved dose (not just the maximum dose).
• Language from the FDA-approved prescribing information stating the indication directly.

P2P calls succeed most when the prescriber ties the drug choice to a specific, measurable patient outcome rather than a general argument about drug class superiority. "My patient lost 3% body weight on phentermine/topiramate over 6 months and has OSA with an AHI of 34, and SURMOUNT-OSA showed a 27.4-event reduction in AHI with tirzepatide" is a stronger P2P argument than any generic efficacy statement 4.

External Review and State Protections

When internal appeals fail, external independent review organizations (IROs) handle the third level. Most states mandate that IROs must make decisions within 45 days for non-urgent cases. For urgent medical need (e.g., a patient with decompensated HFpEF or severe OSA), expedited external review decisions are required within 72 hours. Document the urgency explicitly in the request.

States with step therapy reform laws (as of 2025, more than 30 states have enacted such laws 15) require payers to grant step therapy exceptions when:

• The required step drug is clinically contraindicated.
• The patient previously tried and failed the step drug (even under a prior insurer).
• The required step drug would cause clinically significant adverse effects.
• The patient is stable on the requested drug and a step-down would cause clinical regression.

Billing and CPT Coding for Obesity and Metabolic Visits

Office Visit E/M Codes

Standard E/M codes (99213, 99214, 99215) apply to tirzepatide initiation and follow-up visits. Select the level based on medical decision-making (MDM) complexity, not time, when possible:

• 99213: Low MDM. Appropriate for a straightforward obesity follow-up with no new comorbidities and stable dosing.
• 99214: Moderate MDM. Appropriate when managing tirzepatide titration alongside at least one chronic condition (T2D, hypertension, or dyslipidemia) requiring medication adjustment.
• 99215: High MDM. Appropriate when the patient has multiple chronic conditions requiring independent interpretation of labs, imaging, or specialist input.

Intensive Behavioral Therapy

CMS covers intensive behavioral therapy (IBT) for obesity under G0473 (individual, 15 minutes) and G0447 (individual, 15 minutes, primary care). These codes can be billed separately from the E/M visit on the same date of service using modifier -25 on the E/M code. IBT documentation is also useful evidence in a PA appeal showing that the lifestyle therapy requirement was completed before initiating pharmacotherapy 16.

Diabetes Prevention Program Billing

For patients enrolled in a CDC-recognized DPP, CMS reimburses the program under HCPCS codes G9873-G9890. Documenting DPP enrollment in the chart serves dual purposes: it satisfies many commercial payers' lifestyle therapy step requirement and may qualify the patient for enhanced obesity management benefits under certain Medicare Advantage plans 12.

Manufacturer Savings Programs

Eli Lilly operates savings card programs for both Mounjaro and Zepbound for commercially insured patients who do not have Medicare or Medicaid. Eligible commercially insured patients may pay as little as $25 per 28-day supply through the Mounjaro savings program or $0 for the first month with Zepbound's launch offer (program terms change; verify at LillyDirect). These programs do not apply to federal health programs and cannot be used with Medicare Part D, Medicaid, or any federal employee health benefit plan.

Titration Milestones and the Link to PA Renewals

Tirzepatide starts at 2.5 mg subcutaneously once weekly. The approved titration schedule advances by 2.5 mg increments every 4 weeks: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, then 15 mg as the maintenance dose for maximum efficacy 2. Most payers approve the initial PA for 90 days at 2.5 mg or 5 mg. At the 90-day renewal, submit updated weight or A1c documentation showing measurable response.

A 5% body weight reduction at 16 weeks is the standard clinical benchmark for "adequate response" used by most payers and referenced in obesity pharmacotherapy guidelines 9. In SURMOUNT-1, 91% of tirzepatide 15 mg patients achieved ≥5% weight loss at 72 weeks 11, giving you strong actuarial grounds to argue that a patient who responded at 5% should continue treatment to reach the 10-15% threshold where cardiometabolic benefits are most pronounced.

For T2D patients on Mounjaro, the renewal criterion is typically A1c remaining above a plan-defined threshold (usually >7.0% or >7.5%) or documented stable glycemic control justifying continuation. The 2024 ADA Standards of Care recommend A1c targets individualized to patient characteristics but note that an A1c of <7.0% is appropriate for most non-pregnant adults with T2D 7.

Special Populations and Coverage Edge Cases

Pediatric Patients

Tirzepatide is not FDA-approved for patients under 18 years of age. Do not submit PAs for pediatric obesity with tirzepatide. The SURMOUNT-PEDS trial was ongoing as of 2025 17, and off-label use in adolescents is not supported by current evidence or guidelines.

Pregnancy and Lactation

Both Mounjaro and Zepbound should be discontinued at least 2 months before a planned pregnancy based on the drug's 5-day half-life and the general principle that incretin-based therapies lack adequate safety data in pregnancy 3. ACOG does not currently support GLP-1 or dual agonist use during pregnancy 18.

Patients Switching from a GLP-1 to Tirzepatide

When a patient is switching from semaglutide (Ozempic or Wegovy) to tirzepatide, document the clinical rationale: either inadequate response (<5% weight loss in 16 weeks), intolerable GI adverse effects at the therapeutic dose, or new indication (e.g., OSA) that is specifically labeled for tirzepatide but not semaglutide. Some payers will deny the switch without this documentation, treating it as a lateral formulary move rather than a clinical upgrade. The SURPASS-2 head-to-head data showing tirzepatide's superiority over semaglutide 1 mg in T2D 1 supports efficacy-based switching arguments in a PA appeal.